Center for Cardiovascular Sciences, Albany Medical College, Albany, New York, USA
Received date June 13, 2013; Accepted date June 16, 2013; Published date June 18, 2013
Citation: Yadav VR, Zheng YM, Wang YX (2013) Essential Role of Phospholipase C-g1 in Hypoxia-Induced Pulmonary Vasoconstriction and Hypertension. J Membra Sci Technol 3:e115. doi:10.4172/2155-9589.1000e115
Copyright: © 2013 Yadav VR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at Journal of Membrane Science & Technology
Hypoxia-induced Pulmonary Vasoconstriction (HPV) is an essential physiological process which ensures proper ventilationperfusion matching in pulmonary circulation with the ultimate aim of optimizing systemic oxygen delivery. However, this cellular response can become a key pathological process leading to pulmonary artery hypertension and right heart failure. An increase in intracellular calcium concentration ([Ca2+]i) in Pulmonary Artery Smooth Muscle Cells (PASMCs) plays a crucial role in producing HPV. However, the underlying signaling mechanisms are not completely understood [1-3]. Thus, the identification of the molecular players involved in HPV is imperative for a deeper and broader understanding of hypoxic pulmonary artery hypertension and other related diseases.
Phospholipase C (PLC) is a key enzyme family for numerous physiological and pathological cellular responses in the cardiovascular system. On activation, PLC hydrolyses the plasma membranebound phosphatidylinositol bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 opens IP3 receptors (IP3Rs) on the Sarcoplasmic Reticulum (SR) membrane to induce Ca2+ release. DAG activates protein kinase C to lead Ca2+- dependent cellular responses. Among all known isoforms, PLCγ1 has shown to be highly expressed in the lungs , and involved in reactive oxygen species (ROS)-evoked increase in [Ca2+]i in PC-12 cell line , cultured human venous SMCs  and cultured rat astrocytes . ROS are known to be critical for the hypoxic increase in [Ca2+]i in PAMSCs [1,8]. Taken together, it was conjectured that PLCγ1 would be a major regulator in the hypoxic increase in [Ca2+]i in PASMCs and HPV.
We conducted a series of experiments to test the aforementioned exciting assumption. Our data have revealed that PLCγ1 is activated in pulmonary arteries following acute hypoxic exposure. Equally importantly, lentiviral shRNA-mediated knock-down of PLCγ1 or pharmacological inhibition of PLC significantly reduces hypoxiainduced increase in [Ca2+]i in PASMCs and HPV . It is interesting to note that PLCγ1 enhances survival of MEF cells  and cardiomycytes during oxidative stress . Patterson and coworkers have reported that PLCγ is required for agonist-induced Ca2+ entry in PC12 and A7r5 cells by controlling TRPC3 trafficking and expression on the plasma membrane [12,13]. Homozygous PLCγ1 gene knockout mice show the early embryonic lethality , further reinforcing the functional importance of PLCγ1.
Our very recent studies have further unveiled that acute hypoxic exposure causes significant phosphorylation of PLCγ1 at tyrosine 783, which is regarded as vital for activation of PLCγ1 , in PASMCs . Gene silencing of Rieske Iron-Sulfur Protein (RISP) to inhibit ROS generation at the mitochondrial complex III  fully abolishes the acute hypoxic phosphorylation of PLCγ1 . Similarly, treatment with the mitochondrial complex III inhibitor myxothiazol to block ROS generation [16-18] completely inhibits the hypoxic response as well. Collectively, the hypoxic activation of PLCγ1 in PASMCs is mediated by RISP-dependent mitochondrial ROS production. Whether or not hypoxic activation of PLCγ1 is directly dependent on ROS or ROS mediated interplay molecules is a matter of further investigation. Nevertheless, targeting PLCγ1 on the plasma membrane may provide a viable and important approach in developing new and more effective therapeutic strategies for hypoxic pulmonary artery hypertension and other related diseases.